Clearmind Medicine Inc. CMND Archives

FridayMar 25, 2022 9:00 am

Interactive Session on Psychedelics for Alcoholism, Q&A with Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Management

Clearmind (CSE: CMND) (FSE: CWY0) Management invites leaders, innovators, scientists, doctors, patients, enthusiasts, and luminaries in the psychedelic space to attend a virtual Q&A session on March 30th, focused on the potential treatment of alcohol use and binge drinking based on its psychoactive molecule MEAI. Global leaders and innovators in the psychedelic space will participate in the virtual event and discuss psychedelic therapies and treatments for excessive alcohol consumption and mental disorders. The dedicated team of experts at Clearmind is engaged in developing breakthrough treatments for binge behaviour, alcohol use disorder, binge eating and depression. Adi Zuloff-Shani, PhD, Clearmind’s Chief…

TuesdayMar 22, 2022 9:15 am

Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Announces Next Segment in Far-Reaching ‘Psychedelics for Alcoholism’ Series

Clearmind Medicine (CSE: CMND) (FSE: CWY0), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics, has announced the fifth webinar in its Psychedelics for Alcoholism series. This segment is titled “Psychedelics for Alcoholism, Q&A with Clearmind Management.” Scheduled for March 30, 2022, this insightful event will feature Clearmind CEO Adi Zuloff-Shani and business development VP Mark Haden. The two experts will discuss the effects of alcohol use disorder (“AUD”) and provide an overview of the company’s proprietary psychoactive molecule, MEAI. In addition, the webinar will include a question-and-answer session, during which key personnel will answer questions related…

TuesdayOct 26, 2021 1:53 pm

QualityStocksNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Enters Agreement with Aragen Life Sciences to Produce Innovative Drug Candidate

Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced its entry into a development and supply agreement with Aragen Life Sciences Pvt. Ltd for the production of its innovative molecule, 5-Methoxy-2-aminoindane (“MEAI”). Aragen is a global leader in providing discovery, development and manufacturing solutions for life sciences firms under Good Manufacturing Practices. Under the agreement, Aragen will complete a process optimization and synthesis, manufacturing and supply of MEAI to Clearmind. “Aragen is a world-class, life-sciences company with state-of-the-art manufacturing…

WednesdayOct 13, 2021 1:53 pm

QualityStocksNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Announces Provisional Patent Application Related to Drug-Assisted Psychotherapy Methods

Clearmind Medicine (CSE: CMND) (FSE: CWY0), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, has filed a provisional patent application (“PPA”) with the United States Patent and Trademark Office (“USPTO”). The patent, which was filed on Oct. 8, 2021, covers CMND’s proprietary, novel methods of drug-assisted psychotherapy. According to the company, drug-assisted psychotherapy combines drug and psychological treatments designed to create a superior outcome when used together, including an improved patient-therapist relationship and increased flexibility in the patient’s mind, which allows a patient to explore new…

Site Search

Company Search

Tag: Clearmind Medicine Inc. CMND

Interactive Session on Psychedelics for Alcoholism, Q&A with Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Management

Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Announces Next Segment in Far-Reaching ‘Psychedelics for Alcoholism’ Series

QualityStocksNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Enters Agreement with Aragen Life Sciences to Produce Innovative Drug Candidate

QualityStocksNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) Announces Provisional Patent Application Related to Drug-Assisted Psychotherapy Methods

Market Basics

Newsletter Publishers

Public Companies